O	0	9	Activated	Activate	VBN	B-NP
B-Cell	10	19	platelets	platelet	NNS	I-NP
O	20	27	enhance	enhance	VBP	B-VP
B-Cell	28	35	ovarian	ovarian	JJ	B-NP
I-Cell	36	42	cancer	cancer	NN	I-NP
I-Cell	43	47	cell	cell	NN	I-NP
O	48	56	invasion	invasion	NN	I-NP
O	57	59	in	in	IN	B-PP
O	60	61	a	a	DT	B-NP
B-Cell	62	70	cellular	cellular	JJ	I-NP
O	71	76	model	model	NN	I-NP
O	77	79	of	of	IN	B-PP
O	80	90	metastasis	metastasis	NN	B-NP
O	90	91	.	.	.	O

O	93	102	Increased	Increase	VBN	B-NP
B-Cell	103	111	platelet	platelet	NN	I-NP
O	112	118	counts	count	NNS	I-NP
O	119	122	and	and	CC	O
O	123	131	systemic	systemic	JJ	B-NP
O	132	143	coagulation	coagulation	NN	I-NP
O	144	154	activation	activation	NN	I-NP
O	155	158	are	be	VBP	B-VP
O	159	169	associated	associate	VBN	I-VP
O	170	174	with	with	IN	B-PP
B-Cancer	175	182	ovarian	ovarian	JJ	B-NP
I-Cancer	183	189	cancer	cancer	NN	I-NP
O	190	201	progression	progression	NN	I-NP
O	201	202	.	.	.	O

B-Cell	203	211	Platelet	Platelet	NN	B-NP
O	212	222	activation	activation	NN	I-NP
O	223	229	occurs	occur	VBZ	B-VP
O	230	232	in	in	IN	B-PP
O	233	236	the	the	DT	B-NP
B-Cancer	237	242	tumor	tumor	NN	I-NP
O	243	259	microenvironment	microenvironment	NN	I-NP
O	260	263	and	and	CC	O
O	264	267	may	may	MD	B-VP
O	268	277	influence	influence	VB	I-VP
O	278	283	local	local	JJ	B-NP
O	284	292	invasion	invasion	NN	I-NP
O	293	296	and	and	CC	I-NP
O	297	307	metastasis	metastasis	NN	I-NP
O	307	308	.	.	.	O

O	309	311	We	We	PRP	B-NP
O	312	316	used	use	VBD	B-VP
O	317	318	a	a	DT	B-NP
B-Cell	319	327	cellular	cellular	JJ	I-NP
O	328	333	model	model	NN	I-NP
O	334	336	of	of	IN	B-PP
B-Cancer	337	342	tumor	tumor	NN	B-NP
O	343	351	invasion	invasion	NN	I-NP
O	352	354	to	to	TO	B-VP
O	355	366	investigate	investigate	VB	I-VP
O	367	370	the	the	DT	B-NP
O	371	377	effect	effect	NN	I-NP
O	378	380	of	of	IN	B-PP
O	381	390	activated	activate	VBN	B-NP
B-Cell	391	400	platelets	platelet	NNS	I-NP
O	401	403	on	on	IN	B-PP
O	404	407	the	the	DT	B-NP
O	408	413	human	human	JJ	I-NP
B-Cell	414	421	ovarian	ovarian	JJ	I-NP
I-Cell	422	428	cancer	cancer	NN	I-NP
I-Cell	429	433	cell	cell	NN	I-NP
I-Cell	434	438	line	line	NN	I-NP
O	438	439	,	,	,	O
B-Cell	440	445	SKOV3	SKOV3	NN	B-NP
O	445	446	.	.	.	O

B-Cell	447	452	SKOV3	SKOV3	NN	B-NP
I-Cell	453	458	cells	cell	NNS	I-NP
O	459	463	were	be	VBD	B-VP
O	464	471	exposed	expose	VBN	I-VP
O	472	474	to	to	TO	B-PP
O	475	481	washed	wash	VBN	B-NP
O	481	482	,	,	,	I-NP
O	483	491	thrombin	thrombin	NN	I-NP
O	492	500	receptor	receptor	NN	I-NP
O	501	511	activating	activating	NN	I-NP
O	512	519	peptide	peptide	NN	I-NP
O	520	521	(	(	(	O
O	521	525	TRAP	TRAP	NN	B-NP
O	525	526	)	)	)	O
O	526	527	-	-	HYPH	B-VP
O	527	536	activated	activate	VBN	I-VP
O	537	539	or	or	CC	O
O	540	544	TRAP	TRAP	NN	B-NP
O	544	545	-	-	HYPH	B-NP
O	545	550	naive	naive	JJ	I-NP
B-Cell	551	560	platelets	platelet	NNS	I-NP
O	561	566	under	under	IN	B-PP
O	567	574	various	various	JJ	B-NP
O	575	587	experimental	experimental	JJ	I-NP
O	588	598	conditions	condition	NNS	I-NP
O	598	599	,	,	,	O
O	600	603	and	and	CC	O
B-Cell	604	609	tumor	tumor	NN	B-NP
I-Cell	610	614	cell	cell	NN	I-NP
O	615	623	invasion	invasion	NN	I-NP
O	624	627	was	be	VBD	B-VP
O	628	635	assayed	assay	VBN	I-VP
O	636	638	in	in	IN	B-PP
O	639	647	Matrigel	Matrigel	NNP	B-NP
O	648	656	chambers	chamber	NNS	I-NP
O	656	657	.	.	.	O

O	658	661	The	The	DT	B-NP
O	662	668	effect	effect	NN	I-NP
O	669	671	of	of	IN	B-PP
B-Cell	672	681	platelets	platelet	NNS	B-NP
O	682	684	on	on	IN	B-PP
O	685	688	the	the	DT	B-NP
O	689	696	content	content	NN	I-NP
O	697	699	of	of	IN	B-PP
O	700	709	urokinase	urokinase	NN	B-NP
O	710	721	plasminogen	plasminogen	NN	I-NP
O	722	731	activator	activator	NN	I-NP
O	732	733	(	(	(	O
O	733	736	uPA	uPA	NN	B-NP
O	736	737	)	)	)	O
O	738	741	and	and	CC	O
O	742	746	VEGF	VEGF	NN	B-NP
O	747	749	in	in	IN	B-PP
B-Cell	750	755	SKOV3	SKOV3	NN	B-NP
I-Cell	756	760	cell	cell	NN	I-NP
O	761	772	conditioned	conditioned	JJ	I-NP
O	773	779	medium	medium	NN	I-NP
O	780	783	was	be	VBD	B-VP
O	784	792	measured	measure	VBN	I-VP
O	793	798	using	use	VBG	I-VP
O	799	801	an	an	DT	B-NP
O	802	807	ELISA	ELISA	NN	I-NP
O	808	813	assay	assay	NN	I-NP
O	813	814	.	.	.	O

O	815	819	TRAP	TRAP	NN	B-NP
O	819	820	-	-	HYPH	B-NP
O	820	829	activated	activate	VBN	I-NP
B-Cell	830	839	platelets	platelet	NNS	I-NP
O	840	850	stimulated	stimulate	VBD	B-VP
O	851	852	a	a	DT	B-NP
O	853	857	dose	dose	NN	I-NP
O	857	858	-	-	HYPH	B-NP
O	858	867	dependent	dependent	JJ	I-NP
O	868	876	increase	increase	NN	I-NP
O	877	879	in	in	IN	B-PP
B-Cell	880	885	SKOV3	SKOV3	NN	B-NP
I-Cell	886	890	cell	cell	NN	I-NP
O	891	899	invasion	invasion	NN	I-NP
O	899	900	.	.	.	O

O	901	909	Exposure	Exposure	NN	B-NP
O	910	912	to	to	TO	B-PP
O	913	922	activated	activate	VBN	B-NP
B-Cellular_component	923	931	platelet	platelet	NN	I-NP
I-Cellular_component	932	941	membranes	membrane	NNS	I-NP
O	942	945	and	and	CC	B-PP
O	946	948	to	to	TO	B-PP
O	949	956	soluble	soluble	JJ	B-NP
O	957	965	proteins	protein	NNS	I-NP
O	966	975	contained	contain	VBN	B-VP
O	976	978	in	in	IN	B-PP
O	979	988	activated	activate	VBN	B-NP
B-Cell	989	997	platelet	platelet	NN	I-NP
O	998	1007	releasate	releasate	NN	I-NP
O	1008	1012	both	both	DT	B-NP
O	1013	1024	contributed	contribute	VBD	B-VP
O	1025	1027	to	to	TO	B-PP
O	1028	1031	the	the	DT	B-NP
O	1032	1040	observed	observe	VBN	I-NP
O	1041	1049	increase	increase	NN	I-NP
O	1050	1052	in	in	IN	B-PP
O	1053	1061	invasion	invasion	NN	B-NP
O	1061	1062	.	.	.	O

O	1063	1066	The	The	DT	B-NP
O	1067	1077	inhibition	inhibition	NN	I-NP
O	1078	1080	of	of	IN	B-PP
B-Cell	1081	1089	platelet	platelet	NN	B-NP
O	1090	1100	activation	activation	NN	I-NP
O	1101	1105	with	with	IN	B-PP
O	1106	1119	prostaglandin	prostaglandin	NN	B-NP
O	1120	1122	E1	E1	NN	I-NP
O	1123	1124	(	(	(	O
O	1124	1127	PGE	PGE	NN	B-NP
O	1127	1128	(	(	(	O
O	1128	1129	1	1	CD	B-NP
O	1129	1130	)	)	)	O
O	1130	1131	)	)	)	O
O	1132	1142	attenuated	attenuate	VBD	B-VP
O	1143	1146	the	the	DT	B-NP
O	1147	1155	invasive	invasive	JJ	I-NP
O	1156	1164	capacity	capacity	NN	I-NP
O	1165	1167	of	of	IN	B-PP
B-Cell	1168	1173	SKOV3	SKOV3	NN	B-NP
I-Cell	1174	1179	cells	cell	NNS	I-NP
O	1179	1180	.	.	.	O

O	1181	1189	Exposure	Exposure	NN	B-NP
O	1190	1192	to	to	TO	B-PP
B-Cell	1193	1202	platelets	platelet	NNS	B-NP
O	1203	1211	resulted	result	VBD	B-VP
O	1212	1214	in	in	IN	B-PP
O	1215	1228	significantly	significantly	RB	B-NP
O	1229	1238	increased	increase	VBN	I-NP
O	1239	1242	uPA	uPA	NN	I-NP
O	1243	1246	and	and	CC	I-NP
O	1247	1251	VEGF	VEGF	NN	I-NP
O	1252	1259	content	content	NN	I-NP
O	1260	1262	of	of	IN	B-PP
B-Cell	1263	1268	SKOV3	SKOV3	NN	B-NP
I-Cell	1269	1273	cell	cell	NN	I-NP
O	1274	1285	conditioned	conditioned	JJ	I-NP
O	1286	1292	medium	medium	NN	I-NP
O	1292	1293	.	.	.	O

O	1294	1303	Activated	Activate	VBN	B-NP
B-Cell	1304	1313	platelets	platelet	NNS	I-NP
O	1314	1321	enhance	enhance	VBP	B-VP
B-Cell	1322	1327	SKOV3	SKOV3	NN	B-NP
O	1328	1333	human	human	JJ	I-NP
B-Cell	1334	1341	ovarian	ovarian	JJ	I-NP
I-Cell	1342	1348	cancer	cancer	NN	I-NP
I-Cell	1349	1353	cell	cell	NN	I-NP
O	1354	1362	invasion	invasion	NN	I-NP
O	1363	1370	through	through	IN	B-PP
O	1371	1379	Matrigel	Matrigel	NNP	B-NP
O	1380	1383	and	and	CC	O
O	1384	1392	increase	increase	VB	B-VP
O	1393	1396	the	the	DT	B-NP
O	1397	1403	amount	amount	NN	I-NP
O	1404	1406	of	of	IN	B-PP
O	1407	1410	uPA	uPA	NN	B-NP
O	1411	1414	and	and	CC	I-NP
O	1415	1419	VEGF	VEGF	NN	I-NP
O	1420	1428	secreted	secrete	VBN	B-VP
O	1429	1433	into	into	IN	B-PP
B-Cell	1434	1439	SKOV3	SKOV3	NN	B-NP
I-Cell	1440	1444	cell	cell	NN	I-NP
O	1445	1456	conditioned	conditioned	JJ	I-NP
O	1457	1463	medium	medium	NN	I-NP
O	1463	1464	.	.	.	O

O	1465	1467	If	If	IN	B-SBAR
O	1468	1481	generalizable	generalizable	JJ	B-ADJP
O	1482	1484	to	to	TO	B-PP
O	1485	1495	additional	additional	JJ	B-NP
B-Cell	1496	1500	cell	cell	NN	I-NP
I-Cell	1501	1506	lines	line	NNS	I-NP
O	1507	1510	and	and	CC	O
O	1511	1516	human	human	JJ	B-NP
O	1517	1524	disease	disease	NN	I-NP
O	1524	1525	,	,	,	O
O	1526	1530	this	this	DT	B-NP
O	1531	1542	observation	observation	NN	I-NP
O	1543	1546	may	may	MD	B-VP
O	1547	1556	partially	partially	RB	I-VP
O	1557	1564	explain	explain	VB	I-VP
O	1565	1568	the	the	DT	B-NP
O	1569	1576	adverse	adverse	JJ	I-NP
O	1577	1586	prognosis	prognosis	NN	I-NP
O	1587	1597	associated	associate	VBN	B-VP
O	1598	1602	with	with	IN	B-PP
O	1603	1617	thrombocytosis	thrombocytosis	NN	B-NP
O	1618	1620	in	in	IN	B-PP
B-Cancer	1621	1628	ovarian	ovarian	JJ	B-NP
I-Cancer	1629	1635	cancer	cancer	NN	I-NP
O	1635	1636	.	.	.	O

B-Cell	1637	1646	Platelets	Platelet	NNS	B-NP
O	1646	1647	,	,	,	O
O	1648	1657	therefore	therefore	RB	B-ADVP
O	1657	1658	,	,	,	O
O	1659	1662	may	may	MD	B-VP
O	1663	1672	represent	represent	VB	I-VP
O	1673	1674	a	a	DT	B-NP
O	1675	1684	potential	potential	JJ	I-NP
O	1685	1691	target	target	NN	I-NP
O	1692	1695	for	for	IN	B-PP
O	1696	1707	therapeutic	therapeutic	JJ	B-NP
O	1708	1720	intervention	intervention	NN	I-NP
O	1721	1723	in	in	IN	B-PP
O	1724	1729	human	human	JJ	B-NP
B-Cancer	1730	1737	ovarian	ovarian	JJ	I-NP
I-Cancer	1738	1744	cancer	cancer	NN	I-NP
O	1744	1745	.	.	.	O

